Seizure control and treatment changes in pregnancy: Observations from the EURAP epilepsy pregnancy registry

Epilepsia

Volumn 54, Issue 9, 2013, Pages 1621-1627

  Battino, Dina ^a   Tomson, Torbjörn ^b   Bonizzoni, Erminio ^c   Craig, John ^d   Lindhout, Dick ^e,f   Sabers, Anne ^g   Perucca, Emilio ^h   Vajda, Frank ⁱ  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF MILAN   (Italy)

^d ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^g Rigshospitalet   (Denmark)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antiepileptic drugs; Epilepsy; Pregnancy; Seizures

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; VALPROIC ACID;

ARTICLE; CONCEPTION; CONTROLLED STUDY; DETERIORATION; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EXPOSURE; EPILEPTIC STATE; FEMALE; FIRST TRIMESTER PREGNANCY; GENERALIZED EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL MORTALITY; MONOTHERAPY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; SEIZURE; STILLBIRTH; THIRD TRIMESTER PREGNANCY; TONIC CLONIC SEIZURE;

ANTIEPILEPTIC DRUGS; EPILEPSY; PREGNANCY; SEIZURES;

ANTICONVULSANTS; CARBAMAZEPINE; FEMALE; HUMANS; PHENOBARBITAL; PREGNANCY; PREGNANCY COMPLICATIONS; REGISTRIES; SEIZURES; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 84883740659     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12302     Document Type: Article

References (17)

1. Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J, Mawer G, Nicolaides P, Pickering L, Tunnicliffe L, Chadwick DW,. (2004) The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 75: 1575-1583.
2. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, Harper A, Hulbert D, Lucas S, McClure J, Millward-Sadler H, Neilson J, Nelson-Piercy C, Norman J, O'Herlihy C, Oates M, Shakespeare J, de Swiet M, Williamson C, Beale V, Knight M, Lennox C, Miller A, Parmar D, Rogers J, Springett A,. (2011) Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 118 (Suppl. 1): 1-203.
3. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J,. (2011) Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 96: 643-647.
4. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C,. (2009) Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 50: 1237-1246.
5. Hernandez-Diaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB,. (2012) Comparative safety of antiepileptic drugs during pregnancy. Neurology 78: 1692-1699.
6. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J,. (2006) Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77: 193-198.
7. Öhman I, Beck O, Vitols S, Tomson T,. (2008) Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 49: 1075-1080.
8. Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, Newman M, Stowe ZN,. (2008) Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 70: 2130-2136.
9. Sabers A, Petrenaite V,. (2009) Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia 50: 2163-2166.
10. Teramo K, Hiilesmaa V,. (1982) Pregnancy and fetal complications in epileptic pregnancies. In, Janz D, Dam M, Bossi L, Helge H, Richens A, Schmidt D, (Eds) Epilepsy, pregnancy, and the child. Raven Press, New York, NY, pp. 53-59.
11. The EURAP Study. (2006) Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 66: 354-360.
12. Thomas SV, Syam U, Devi JS,. (2012) Predictors of seizures during pregnancy in women with epilepsy. Epilepsia 53: e85-e88.
13. Tomson T, Battino D,. (2012) Teratogenic effects of antiepileptic drugs. Lancet Neurol 11: 803-813.
14. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F,. (2011) Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10: 609-617.
15. Tomson T, Johannessen Landmark C, Battino D,. (2013) Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 54: 405-414.
16. Vajda F, Solinas C, Graham J, Hitchcock A, Eadie M,. (2006) The case for lamotrigine monitoring in pregnancy. J Clin Neurosci 13: 103-104.
17. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE,. (2009) Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 50: 2130-2139.